Neuromyelitis Optica Spectrum Disorder (NMOSD): Soliris and IVIG Options
NMOSD can be mistaken for MS but requires its own targeted treatment approach. Two infusion therapies offer meaningful options for preventing relapses.
What is NMOSD?
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition affecting the central nervous system, primarily the optic nerves and spinal cord. It's caused by antibodies attacking a protein (aquaporin-4) on cells that support nerve function, leading to attacks of vision loss, eye pain, and weakness or numbness that can be severe.
NMOSD was once often mistaken for multiple sclerosis, but it's a distinct condition, and the treatments that work well for MS aren't necessarily effective, or can even worsen, NMOSD, which is why an accurate diagnosis matters.
How infusion therapy helps
Soliris (eculizumab) is approved specifically for NMOSD in patients who test positive for the aquaporin-4 antibody, working by blocking part of the immune system (complement) involved in the nerve damage, aimed at preventing relapses rather than treating them after the fact.
IVIG is also used, particularly during acute attacks or for patients who don't respond well to other options, helping to calm the immune response driving the disease.
Diagnosed with NMOSD?
Getting the right infusion therapy for NMOSD specifically, not MS treatment, matters. Our team coordinates closely with your neurologist.
Call (551) 336-5580This article is for general educational purposes and is not a substitute for medical advice. Treatment decisions should always be made with your physician based on your individual diagnosis and health history.